The effect of aspirin on atherogenic diet-induced diabetes mellitus

Basic and Clinical Pharmacology and Toxicology

Volumn 108, Issue 6, 2011, Pages 371-377

  Sethi, Apoorva ^a   Parmar, Hamendra Singh ^a   Kumar, Anil ^a  

^a DEVI AHILYA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMYLASE; CALCIUM; CHOLESTEROL; GLYCOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NITRITE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOCYTE; AMYLASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENIC DIET; CALCIUM TRANSPORT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; GLUCOSE BLOOD LEVEL; GLYCOGEN LIVER LEVEL; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID BLOOD LEVEL; LIPID PEROXIDATION; MALE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS; DIET, ATHEROGENIC; FREE RADICAL SCAVENGERS; HYPERCHOLESTEROLEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPID PEROXIDATION; LIPIDS; LIVER; MALE; NITRIC OXIDE; OXIDATIVE STRESS; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 79955963388     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00663.x     Document Type: Article

References (50)

1. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004;431:405-6.
2. Van Kruijsdijk RC, Vander Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009;18:2569-78.
3. Cook GP, Savic S, Wittmann M, McDermott MF. The NLRP3 inflammasome, a target for therapy in diverse diasease states. Eur J Immunol 2010;40:631-4.
4. Van der Crabben SN, Allick G, Ackeermans MT, Endert E, Romijn JA, Sauerwein HP. Prolonged fasting induces peripheral insulin resistance, which is not ameliorated by high-dose salicylate. J Clin Endocrinol Metab 2008;93:638-41.
5. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-23.
6. Dragomir E, Tircol M, Manduteanu I, Voinea M, Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 2006;44:440-9.
7. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H et al. Recent advances in the relationship between obesity, inflammation and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
8. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 2008;31:S161-4.
9. Pelika'nova T. Treatment of diabetes mellitus in metabolic syndrome. Vnitr Lek 2009;55:637-45.
10. Zarich SW. Antidiabetic agents and cardiovascular risk in type 2 diabetes. Nat Rev Endocrinol 2009;5:500-6.
11. Roffi M, Eberli FR. Diabetes and acute coronary syndromes. Best Pract Res Clin Endocrinol Metab 2009;23:305-16.
12. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. Am J Clin Nutr 1987;45:564-9.
13. Hermann M, Kapiotis S, Hofbauer R, Exner M, Seelos C, Held I et al. Salicylate inhibits LDL oxidation initiated by superoxide/nitric oxide radicals. FEBS Lett 1999;445:212-4.
14. Das UN. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 2000;215:145-52.
15. Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, Kohno M, Ogawa N. Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging nitric oxide radicals. J Neurochem 2001;76:1895-904.
16. Prasad K, Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther 2003;8:61-9.
17. Tous M, Ferré N, Vilella E, Riu F, Camps J, Joven J. Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Basic Clin Pharmacol Toxicol 2004;95:15-9.
18. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005;54:S97-107.
19. Tauseef M, Sharma KK, Fahim M. Aspirin restores normal barofeflex function in hypercholesterolemic rats by its antioxidative action. Eur J Pharmacol 2007;556:136-43.
20. Dabhi JK, Solanki JK, Mehta A. Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor-an animal study. Indian J Exp Biol 2008;46:476-781.
21. Deepa PR, Varalakshmi P. Salubrious effect of low molecular weight heparin on atherogenic diet-induced cardiac, hepatic and renal lipid peroxidation and collapse of antioxidant defences. Mol Cell Biochem 2003;254:111-6.
22. Parmar HS, Kar A. Atherogenic diet induced diabetes mellitus: involvement of thyroid hormones. Eur J Pharmacol 2007;570:244-8.
23. Parmar HS, Kar A. Protective role of Citrus sinensis, Punica granatum and Musa paradisiaca peels against diet-induced atherosclerosis and thyroid dysfunctions in rats. Nutr Res 2007;27:710-8.
24. Parmar HS, Kar A. Possible amelioration of atherogenic diet induced dyslipidemia, hypothyroidism and hyperglycemia by the peel extracts of Mangifera indica, Cucumis melo and Citrullus vulgaris fruits in rats. Biofactors 2008;33:13-24.
25. Deepa PR, Varalakshmi P. Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis. Clin Chim Acta 2004;339:105-15.
26. Parmar HS, Kar A. Comparative analysis of free radical scavenging potential of some fruit peel extracts by in vitro methods. Drug Discov Ther 2009;3:49-55.
27. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
28. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-5.
29. Fossati P, Lorenzo P. Serum triglycerides determination colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-80.
30. Ranson JH. Acute pancreatitis. Curr Probl Surg 1979;16:1-84.
31. Friedwald WT, Levy RI, Fredrickson DC. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
32. Carroll NV, Longley RW, Roe JH. The determination of glycogen in liver and heart muscle by use of anthrone reagent. J Biol Chem 1959;220:583-93.
33. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
34. Barnett RN, Skodon SB, Goldberg MH. Performance of "kits" used for clinical chemical analysis of calcium in serum. Am J Clin Pathol 1973;59:836-45.
35. Vimal V, Devaki T. Linear furanocoumarin protects rat myocardium against lipid peroxidation and membrane damage during experimental myocardial injury. Biomed Pharmacother 2004;58:393-400.
36. Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-6.
37. Shimabukuro M, Zhou YT, Levi M, Unger RH et al. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998;95:2498-502.
38. Jatwa R, Kar A. Cardio-protective role of terazosin is possibly mediated through alteration in thyroid function. Eur J Pharmacol 2006;551:87-91.
39. Kaneto H, Kawamori D, Matsuoka TA, Kajimoto Y, Yamasaki Y. Oxidative stress and pancreatic beta-cell dysfunction. Am J Ther 2005;12:529-33.
40. Lenzen S. Oxidative stress: the vulnerable beta-cell. Biochem Soc Trans 2008;36:343-7.
41. Deepa PR, Varalakshmi P. Favourable modulation of the inflammatory changes in hypercholesterolemic atherogenesis by a low- molecular-weight heparin derivative. Int J Cardiol 2006;106:338-47.
42. Diaz GB, Paladini AA, Garcia ME, Gagliardino JJ. Changes induced by hypothyroidism in insulin secretion and in the properties of islet plasma membranes. Arch Int Physiol Biochim Biophys 1993;101:263-9.
43. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: Over-the-counter drugs that interact to stimulate thermogenesis in obese. Nutrition 1989;5:7-9.
44. Krieger DR, Daly PA, Dulloo AG, Ransil BJ, Young JB, Landsberg L. Ephedrine, caffeine and aspirin promote weight loss in obese subjects. Trans Assoc Am Physicians 1990;103:307-12.
45. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obes Relat Metab Disord 1993;17:S73-8.
46. Wilson SH, Kennedy FP, Garratt KN. Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus. Drugs Aging 2001;18:325-33.
47. Torella R, Giugliano D, Siniscalchio N, Sgambato S, D'Onofrio F. Influence of acetylsalicylic acid on plasma glucose, insulin, glucagon, and growth hormone levels following tolbutamide stimulation in man. Metabolism 1979;28:887-9.
48. Giugliano D, Di Pinto P, Torella R, Frascolla N, Saccomanno F, Passariello N. A role for endogenous prostaglandin E in biphasic pattern of insulin release in humans. Am J Physiol 1983;245:E591-7.
49. Ganong W. Review of Medical Physiology. 17 th edn. Applenton and Lange; 2005.
50. Reiser PJ, Kline WO, Vaghy PL. Induction of neuronal type nitric oxide synthase in skeletal muscle by chronic electrical stimulation in vivo. J Appl Physiol 1997;82:1250-5.